# E. coli Competent Cells



## **Technical Bulletin No. 095**

INSTRUCTIONS FOR USE OF PRODUCTS L1001, L1011, L1191, L1201, L2001 AND L2011. PLEASE DISCARD PREVIOUS VERSIONS. All technical literature is available on the Internet at www.promega.com Please visit the web site to verify that you are using the most current version of this Technical Bulletin.

Ι.	Description	1
П.	Product Components	2
III.	Standard Transformation Protocol	2
IV.	Calculation of Transformation Efficiency	3
V.	Composition of Buffers and Solutions	4
VI.	References	4
Experienced User's Protocol		

## I. Description

Promega's E. coli Competent Cells are prepared according to a modified procedure of Hanahan (1). The competent cells can be used for many standard molecular biology applications. Competent cells of strains HB101 and JM109 are available for convenient transformation in two efficiencies: High Efficiency at greater than 108cfu/µg and Subcloning Efficiency at greater than 107cfu/µg. JM109 cells (2) are an ideal host for many molecular biology applications. HB101 cells (3) are useful for cloning in vectors that do not require  $\alpha$ -complementation for blue/white screening. The BMH 71-18 *mutS* strain is suitable for use in in vitro mutagenesis procedures where a repair (-) strain is required. BL21(DE3)pLysS cells<sup>(a)</sup> can be used with protein expression vectors that are under the control of the T7 promoter, such as pET vectors. This strain is lysogenic for lambda-DE3 (4), which contains the T7 bacteriophage gene 1, encoding T7 RNA polymerase (5) under the control of the lac UV5 promoter. BL21(DE3)pLysS also contains the pLysS plasmid, which carries the gene encoding T7 lysozyme. T7 lysozyme lowers the background expression level of target genes under the control of the T7 promoter but does not interfere with the level of expression achieved following induction with IPTG. For genotypic information on Promega's E. coli Competent Cells, see Table 1.

## Table 1. Genotypes of E. coli Competent Cells Offered by Promega.

Strain	Genotype
BL21(DE3)pLysS	F <sup>-</sup> , <i>omp</i> T, <i>hsd</i> S <sub>B</sub> ( $r_B^-$ , $m_B^-$ ), <i>dcm</i> , <i>gal</i> , $\lambda$ (DE3), pLysS, Cm <sup>r</sup>
BMH 71-18 <i>mut</i> S	<i>thi, sup</i> E, ∆( <i>lac-pro</i> AB), [ <i>mut</i> S::Tn10], [F′, <i>pro</i> AB,
	<i>laq</i> l9Z∆M15]
HB101	F−, <i>thi</i> -1, <i>hsd</i> S20 (r <sub>B</sub> −, m <sub>B</sub> −), <i>sup</i> E44, <i>rec</i> A13, <i>ara</i> -14,
	<i>leu</i> B6, proA2, <i>lac</i> Y1, <i>gal</i> K2, <i>rpsL</i> 20 (str <sup>r</sup> ), <i>xyl</i> -5, <i>mtl</i> -1
JM109	<i>end</i> A1, <i>rec</i> A1, <i>gyr</i> A96, <i>thi</i> , <i>hsd</i> R17 (r <sub>k</sub> -, m <sub>k</sub> +), <i>rel</i> A1,
	supE44, ∆( <i>lac-pro</i> AB), [F′, <i>tra</i> D36, proAB, <i>laq</i> l٩Z∆M15]





## II. Product Components

Product	Size	Cat.#
JM109 Competent Cells, High Efficiency	1ml	L2001
(>10 <sup>8</sup> cfu/µg)	(5 × 200µl)	
JM109 Competent Cells, Subcloning Efficiency	1ml	L1001
(>10 <sup>7</sup> cfu/µg)	(5 × 200µl)	
HB101 Competent Cells, High Efficiency	1ml	L2011
<u>(&gt;10<sup>8</sup>cfu/µg)</u>	(5 × 200µl)	
HB101 Competent Cells, Subcloning Efficiency	1ml	L1011
(>10 <sup>7</sup> cfu/µg)	(5 × 200µl)	
BL21(DE3)pLysS Competent Cells <sup>(a)</sup>	1ml	L1191
(>10 <sup>6</sup> cfu/µg)	(5 × 200µl)	
BMH 71-18 mutS Competent Cells	1ml	L1201
<u>(&gt;10<sup>7</sup>cfu/µg)</u>	(5 × 200µl)	

**Storage Conditions:** Always store Competent Cells at –70°C. Thaw on ice when ready for use. **Do not refreeze thawed, unused aliquots.** 

All cells are supplied in 200µl aliquots and are provided with 3ng of Competent Cells Control DNA for use as a positive control. Typically, 100µl of Competent Cells are required for standard transformations.

## III. Standard Transformation Protocol

## Materials to Be Supplied by the User

(Solution compositions are provided in Section V.)

- LB or SOC medium
- LB plates with antibiotic
- 17 × 100mm polypropylene culture tubes, sterile (e.g., Falcon<sup>®</sup> 2059)
- IPTG (Cat.# V3955; optional, see Note 4)
- X-Gal (Cat.# V3941; optional, see Note 4)
- Chill sterile 17 × 100mm polypropylene culture tubes on ice, one per transformation (e.g., Falcon<sup>®</sup> 2059). Use of a standard microcentrifuge tube reduces the transformation efficiency by approximately 50% due to inefficient heat-shock treatment of the cells.
- Remove frozen Competent Cells from -70°C and place on ice for 5 minutes, or until just thawed. Once the cells have thawed, pipet quickly or use chilled (4°C) pipette tips to prevent the cells from warming above 4°C.
- 3. Gently mix the thawed Competent Cells by flicking the tube, and transfer 100µl to each of the chilled culture tubes.
- Add 1–50ng of DNA (in a volume not greater than 10µl) per 100µl of Competent Cells. Move the pipette tip through the cells while dispensing. Quickly flick the tube several times.
- 5. Immediately return the tubes to ice for 10 minutes.
- 6. Heat-shock the cells for 45–50 seconds in a water bath at exactly 42°C. **Do not shake.**
- 7. Immediately place the tubes on ice for 2 minutes.

Promega Corporation · 2800 Woods Hollow Road · Madison, WI 53711-5399 USA · Toll Free in USA 800-356-9526 · Telephone 608-274-4330 · Fax 608-277-2516 · www.promega.com
Part# TB095
Page 2
Printed in USA.
Revised 4/00



Note: To determine the transformation efficiency, we recommend using 1µl (0.1ng) of Competent Cells Control DNA at Step 4.

Promega Corporation - 2800 Woods Hollow Road - Madison. WI 53711-5399 USA - Toll Free in USA 800-356-9526 - Telephone 608-274-4330 - Fax 608-277-2516 - www.promega.com Printed in USA. Part# TB095 Revised 4/00 Page 3

- 8. Add 900µl of cold (4°C) SOC medium to each transformation reaction, and
- incubate for 60 minutes at 37°C with shaking (approximately 225rpm). 9. For each transformation reaction, we recommend diluting the cells 1:10 and 1:100 and plating 100µl of the undiluted. 1:10 and 1:100 dilutions on antibiotic plates (see Notes 1–3). Incubate the plates at 37°C for 12–14 hours.

## Notes:

- 1. For transformations using the Competent Cells Control DNA, we recommend diluting the cells 1:10 and then plating 100µl on LB/ampicillin plates.
- Do not dilute BL21(DE3)pLysS Competent Cells; spread 100µl of these cells directly onto antibiotic plates.
- 3. If desired, pellet the cells by centrifugation at  $1,000 \times q$  for 10 minutes, then resuspend in 200µl of SOC or LB medium and plate (see margin note).
- 4. Blue/white screening can be used with a variety of vectors in conjunction with JM109 Competent Cells. To use blue/white color screening for recombinants. plate the transformed cells on LB plates containing 100µg/ml ampicillin, 0.5mM IPTG (Cat.# V3955) and 40µg/ml X-Gal (Cat.# V3941). Incubate overnight at 37°C.

An alternative to preparing plates containing X-Gal and IPTG is to spread 20µl of 50mg/ml X-Gal and 100µl of 0.1M IPTG onto LB ampicillin plates and allow these components to absorb for 30 minutes at 37°C prior to plating cells.

5. Solutions and media containing tetracycline must be stored protected from light in order to maintain potency.

## IV. Calculation of Transformation Efficiency (Colony Forming Units [cfu])

Transformation efficiency is defined as the number of colony forming units (cfu) produced by 1µg of Competent Cells Control DNA (supercoiled plasmid DNA) and is measured by performing a control transformation reaction using a known quantity of DNA, typically 0.1ng, then calculating the number of cfu formed per microgram DNA.

## Equation for Transformation Efficiency (cfu/µg)

 $\frac{\text{cfu on control plate}}{\text{ng of Competent Cells Control DNA plated}} \times \frac{1 \times 10^{3} \text{ng}}{\mu \text{g}}$ 

## Example

After adding 900µl SOC medium to 100µl competent cells that have been transformed with 0.1ng Competent Cells Control DNA, transfer 100µl (equivalent to 0.01ngDNA) to 900µl SOC medium and plate 100µl (equivalent to 0.001ng DNA). If 100 colonies are observed on the plate, the transformation efficiency is:

 $\frac{100cfu}{0.001ng} \times \frac{1 \times 10^3 ng}{\mu g} = 1 \times 10^8 cfu/\mu g$ 

**Note:** Transformation with ligated plasmid DNA will produce fewer colonies than transformation with supercoiled plasmid DNA.

Note: Use high-quality deionized water (e.g., MilliQ<sup>®</sup> or NANOpure<sup>®</sup>) for SOC medium (see recipe in Section V). If LB or other media is used, transformation efficiencies will be reduced.

Note: HB101 and BL21(DE3)pLysS Competent Cells cannot be used for blue/white color screening.

Note: The Competent Cells Control DNA (pGEM®-3Z Vector(b)) is supplied at a concentration of 0.1ng/µl in TE buffer.





## V. Composition of Buffers and Solutions

#### glucose, 2M

180.16g glucose

Add distilled water to 500ml, filtersterilize through a  $0.2\mu m$  filter unit and store in aliquots at  $-20^{\circ}C$ . Stable for 1 year.

## IPTG stock solution, 0.1M

1.2g IPTG (Cat.# V3955)

Add water to 50ml final volume. Filter-sterilize through a 0.2 $\mu$ m filter unit and store at 4°C.

## LB medium with ampicillin

10g/L	Bacto <sup>®</sup> -Tryptone
-------	------------------------------

- 5g/L Bacto®-Yeast Extract
- 5g/L NaCl

Adjust the pH to 7.5 with NaOH. Autoclave to sterilize. Allow the autoclaved medium to cool to 55°C and add ampicillin (final concentration 100µg/ml). For LB plates, include 15g agar prior to autoclaving.

#### X-Gal

Available from Promega (Cat.# V3941) at a concentration of 50mg/ml in dimethylformamide.

#### Mg<sup>2+</sup> stock solution, 2M

101.5g MgCl<sub>2</sub> • 6H<sub>2</sub>O 123.3g MgSO<sub>4</sub> • 7H<sub>2</sub>O

Add distilled water to 500ml and filtersterilize through a 0.2µm filter unit.

**Note:** Filter-sterilizing units should be prerinsed with distilled water before use to remove any toxic material.

## SOC medium

- 2.0g Bacto®-tryptone
- 0.5g Bacto®-yeast extract
- 1ml 1M NaCl
- 0.25ml 1M KCl 1ml Mg<sup>2+</sup> stock
  - (1M MgCl<sub>2</sub> 6H<sub>2</sub>O,
  - 1M MgSO<sub>4</sub> 7H<sub>2</sub>O),
  - filter-sterilized
  - 1ml 2M glucose, filter-sterilized

Bring to 100ml with distilled water.

Add Bacto<sup>®</sup>-tryptone, Bacto<sup>®</sup>-yeast extract, NaCl and KCl to 97ml distilled water. Stir to dissolve. Autoclave and cool to room temperature. Add 2M Mg<sup>2+</sup> stock and 2M glucose stock, each to a final concentration 20mM. Filter the complete medium through a 0.2µm filter unit. The pH should be 7.0.

## VI. References

- 1 Hanahan, D. (1985) In: DNA Cloning, Vol. 1, Glover, D., ed., IRL Press, Ltd., 109.
- 2. Yanisch-Perron, C., Vieira, J. and Messing, J. (1985) Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene* **33**, 103.
- 3. Lacks, S. and Greenberg, B. (1977) Complementary specificity of restriction endonucleases of *Diplococcus pneumoniae* with respect to DNA methylation. *J. Mol. Biol.* **114**, 153.
- 4. Studier, F.W. and Moffatt, B.A. (1986) Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. *J. Mol. Biol.* **189**, 113.
- 5. Davanloo, P. *et al.* (1984) Cloning and expression of the gene for bacteriophage T7 RNA polymerase. *Proc. Natl. Acad. Sci. USA* **81**, 2035.

(a)Usage restrictions apply to Bacterial Strains JM109(DE3) and BL21(DE3)pLysS, to the following Promega products that include these bacterial strains (pGEMEX®-1 and pGEMEX®-2 Vectors) and to any derivatives thereof. Please read the following statement describing these restrictions before purchasing any of these products.

#### Usage Restrictions for the T7 Expression System

The T7 expression system is based on technology developed at Brookhaven National Laboratory under contract with the U.S. Department of Energy and is the subject of patents and patent applications assigned to Associated Universities, Inc. (AUI). This technology, including bacteria, phages and plasmids that carry the gene for T7 RNA Polymerase, is to be used for academic or nonprofit laboratory or licensed commercial research purposes only. By accepting or using the T7 expression technology you agree to be bound by the following conditions set forth by AUI. The initial purchaser may refuse to accept the conditions of this notice by returning this product and the enclosed materials to Promega unused. Academic and Non-Profit Laboratories

No materials that contain the cloned gene for T7 RNA polymerase may be distributed further to third parties outside of your laboratory, unless the recipient receives a copy of this assurance notice and agrees to be bound by its terms. This limitation applies to Bacterial Strain JM109(DE3) and BL21(DE3)pLysS, to the following Promega products that include these bacterial strains (pGEMEX®-1 and pGEMEX®-2 Vectors, pET-5 and pET-9 Vectors, and all pET Vector Systems), and to any derivatives thereof.

**Commercial Laboratories** 

A license is required for any commercial use of the T7 expression system, including use of the T7 system for research purposes or for production purposes by any commercial entity. Information about commercial licenses may be obtained from the Licensing Office, Brookhaven National Laboratory, Upton, New York, 11973, Telephone: 516-282-3312, FAX: 516-282-3729.

(b)U.S. Pat. No. 4,766,072 has been issued to Promega Corporation for transcription vectors having two different bacteriophage RNA polymerase promoter sequences separated by a series of unique restriction sites into which foreign DNA can be inserted.

© 1990–2000 Promega Corporation. All Rights Reserved.

pGEM and pGEMEX are trademarks of Promega Corporation and are registered with the U.S. Patent and Trademark Office.

Bacto is a registered trademark of Difco Laboratories. Falcon is a registered trademark of Becton, Dickinson and Company. MilliQ is a registered trademark of Millipore Corporation. NANOpure is a registered trademark of Barnstead/Thermolyne. **Promega Corporation** 

All prices and specifications are subject to change without prior notice.



2800 Woods Hollow Road Madison, WI 53711-5399

Telephone

Fax

Internet

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.

Promega Corporation - 2800 Woods Hollow Road - Madison. WI 53711-5399 USA - Toll Free in USA 800-356-9526 - Telephone 608-274-4330 - Fax 608-277-2516 - www.promega.com Printed in USA. Part# TB095 Revised 4/00

1ISA

608-274-4330

608-277-2516

www.promega.com



## E. coli Competent Cells: Experienced User's Protocol

This quick protocol is intended as an easy-to-follow reminder for experienced users. Please follow the complete protocol (Section III) the first time you use *E. coli* Competent Cells.

Standard	1.	Chill sterile $17 \times 100$ mm polypropylene culture tubes on ice.
Transformation Protocol	2.	Thaw frozen Competent Cells on ice for 5 minutes.
(Section III)	3.	Gently mix the thawed Competent Cells. Transfer 100µl to each of the chilled culture tubes.
	4.	Add 1–50ng of DNA or 0.1ng Competent Cells Control DNA per 100µl of Competent Cells. Quickly flick the tube several times. (Use Competent Cells Control DNA to determine transformation efficiency.)
	5.	Immediately return the tubes to ice for 10 minutes.
	6.	Heat-shock the cells for 45–50 seconds in a water bath at exactly 42°C. <b>Do not shake.</b>
	7.	Immediately place the tubes on ice for 2 minutes.
	8.	Add 900 $\mu$ I of cold (4°C) SOC medium to each transformation reaction Incubate for 60 minutes at 37°C with shaking.
	9.	For each transformation reaction, dilute the cells 1:10 and 1:100. Plate $100\mu$ of the undiluted, 1:10 and 1:100 dilutions on antibiotic plates. Incubate the plates at 37°C for 12–14 hours.
		For the control, dilute the cells 1:10. Plate 100µl (0.001ng) on LB/ampicillin plates. If using BL21(DE3)pLysS Competent Cells, see Section III, Note 2.